Drug Mingconde anti-cancer drug Tibsovo (ivosidenib) a global clinical Phase 3 trial reaches the main end

bile duct cancer is a rare malignant tumor, according to the occurrence of the site can be divided into hepatic biliary tube cancer and hepatic exobilal bile duct cancerExisting local treatment options include surgery, radiotherapy and other ablation therapy, and there is no approved systemic treatmentFor progressive bile duct cancer, chemotherapy options are limited and molecular targeting is expectedrecently, Drugpartner Agios Pharmaceuticals(http:// announcedthat its anti-cancerdrug(http://Tvosisob,
a global clinical
http://reached its main endpointPatients with bile duct cancer who carried susceptible citric acid dehydrogenase-1 (IDH1) gene mutations were treated with Tibosovo after chemotherapy, and there was a significant improvement in the no-progression phase compared to the placebo groupthe drug's safety is consistent with previously published dataTibsovo targets the mutant IDH1IDH1 and IDH2 are metabolic enzymes that normally help break down nutrients and generate energy for cells When mutationoccuroccuroccuroccuroccuroccuroccuroccur, IDH causes the metabolite d-2-hydroxyl dysacidtlyacid (2-HG) level to rise, blocking the normal differentiation of cells and promoting rapid cell proliferation IDH mutations are common in a variety of blood cancers and solid tumors, including acute myeloid leukemia (AML) and bile duct cancer Nearly one in five cases of hepatic bile duct cancer carry the IDH1 gene mutation the study
a clinical phase 3 trial called ClarIDHy recruited patients with bile duct cancer who had received 1 to 2 treatments, were in advanced stages, and were tested for (http:// carrying the mutation of the IDH1 gene As of January 31, 2019, a total of 185 patients were randomly grouped for oral Tibsovo or placebo treatment primary endpoint symbiotic survival assessed by independent radiology review, secondary endpoints include progression less than the researchers assessed, safety and tolerance, total remission rate, total survival rate, reaction duration, pharmacokinetics/pharmacodynamics, quality of life assessment, etc 　　Agios is expected to submit a complete analysis (http:// for clinical trials at the European Society of Oncology Conference (http:// at the end of September, and plans to submit a application for a new drug (http:// supplement
tothein for Tibsovo's treatment of bile duct cancer by the end of the year